KRAS and non-small cell lung carcinoma: Recently, an exon 2 p.G12C Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) mutation was introduced in the arena of positive predictive biomarkers to be tested for treatment selection in patients with metastatic non‐small cell lung cancer (NSCLC).1